Murray Korc

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7930844/publications.pdf Version: 2024-02-01



MUDDAYKODC

#	Article	IF	CITATIONS
1	The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. , 2022, 236, 108111.		25
2	Trials and tribulations of pancreatic cancer immunotherapy. Cancer Letters, 2021, 504, 1-14.	3.2	37
3	The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Frontiers in Oncology, 2021, 11, 688377.	1.3	82
4	FGFR4 Inhibitor BLU9931 Attenuates Pancreatic Cancer Cell Proliferation and Invasion While Inducing Senescence: Evidence for Senolytic Therapy Potential in Pancreatic Cancer. Cancers, 2020, 12, 2976.	1.7	13
5	Pathogenesis of Pancreatic Cancer-Related Diabetes Mellitus. Pancreas, 2019, 48, 594-597.	0.5	7
6	Circulating Thrombospondin-2 enhances prediction of malignant intraductal papillary mucinous neoplasm. American Journal of Surgery, 2019, 217, 425-428.	0.9	10
7	Cancer-associated cachexia. Nature Reviews Disease Primers, 2018, 4, 17105.	18.1	908
8	Biomimetic and enzyme-responsive dynamic hydrogels for studying cell-matrix interactions in pancreatic ductal adenocarcinoma. Biomaterials, 2018, 160, 24-36.	5.7	97
9	Cancer Exosomes for Early Pancreatic Cancer Diagnosis and Role in Metastasis. , 2018, , 1361-1377.		0
10	Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis. Pancreas, 2018, 47, 1239-1243.	0.5	32
11	Beyond Kras: MYC Rules in Pancreatic Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2018, 6, 223-224.	2.3	9
12	Designer hydrogels: Shedding light on the physical chemistry of the pancreatic cancer microenvironment. Cancer Letters, 2018, 436, 22-27.	3.2	22
13	A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-MET co-expressing metastatic pancreatic adenocarcinoma Journal of Clinical Oncology, 2018, 36, TPS4157-TPS4157.	0.8	0
14	Pancreatic cancer: Stroma and its current and emerging targeted therapies. Cancer Letters, 2017, 391, 38-49.	3.2	136
15	A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. Cancer Letters, 2017, 393, 86-93.	3.2	276
16	Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. Diabetes, 2017, 66, 1103-1110.	0.3	311
17	Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study. International Journal of Cancer, 2017, 141, 905-915.	2.3	48
18	Tobacco and alcohol as risk factors for pancreatic cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2017, 31, 529-536.	1.0	72

MURRAY KORC

#	Article	IF	CITATIONS
19	Enzyme-mediated stiffening hydrogels for probing activation of pancreatic stellate cells. Acta Biomaterialia, 2017, 48, 258-269.	4.1	64
20	Cancer Exosomes for Early Pancreatic Cancer Diagnosis and Role in Metastasis. , 2017, , 1-17.		1
21	Gastrin-Releasing Peptide and Glucose Metabolism Following Pancreatitis. Gastroenterology Research, 2017, 10, 224-234.	0.4	21
22	Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers. Oncotarget, 2017, 8, 39963-39977.	0.8	38
23	Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. The Lancet Gastroenterology and Hepatology, 2016, 1, 226-237.	3.7	318
24	MicroRNA Expression in a Readily Accessible Common Hepatic Artery Lymph Node Predicts Time to Pancreatic Cancer Recurrence Postresection. Journal of Gastrointestinal Surgery, 2016, 20, 1699-1706.	0.9	6
25	Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models. Molecular Cancer Therapeutics, 2016, 15, 2722-2732.	1.9	91
26	Modular and Adaptable Tumor Niche Prepared from Visible Light Initiated Thiol-Norbornene Photopolymerization. Biomacromolecules, 2016, 17, 3872-3882.	2.6	50
27	Pancreatic cancer. Nature Reviews Disease Primers, 2016, 2, 16022.	18.1	1,301
28	Sugar-Coated Proteins Pave the Way to Improving Pancreatic Cancer Diagnosis. Cellular and Molecular Gastroenterology and Hepatology, 2016, 2, 118-119.	2.3	5
29	Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model. Cancer Letters, 2016, 379, 143-153.	3.2	31
30	Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma. Cancer Letters, 2016, 381, 201-210.	3.2	46
31	Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip. Cancer Letters, 2016, 380, 319-329.	3.2	41
32	Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes. Oncotarget, 2016, 7, 323-341.	0.8	33
33	TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis. Oncotarget, 2015, 6, 7504-7521.	0.8	42
34	Pancreatic Cancer–Associated Diabetes Is an "Exosomopathy― Clinical Cancer Research, 2015, 21, 1508-1510.	3.2	27
35	Response to Le Large et al American Journal of Gastroenterology, 2015, 110, 769-770.	0.2	0
36	Pathophysiological role of microRNA-29 in pancreatic cancer stroma. Scientific Reports, 2015, 5, 11450.	1.6	59

MURRAY KORC

#	Article	IF	CITATIONS
37	Label-Free Nanoplasmonic-Based Short Noncoding RNA Sensing at Attomolar Concentrations Allows for Quantitative and Highly Specific Assay of MicroRNA-10b in Biological Fluids and Circulating Exosomes. ACS Nano, 2015, 9, 11075-11089.	7.3	203
38	DUSP1 Is a Novel Target for Enhancing Pancreatic Cancer Cell Sensitivity to Gemcitabine. PLoS ONE, 2014, 9, e84982.	1.1	51
39	Critical role of NF-κB in pancreatic cancer. Oncotarget, 2014, 5, 10969-10975.	0.8	121
40	p38 MAPK in Pancreatic Cancer: Finding a Protective Needle in the Haystack. Clinical Cancer Research, 2014, 20, 5866-5868.	3.2	9
41	A Pilot Study to Develop a Diagnostic Test for Pancreatic Ductal Adenocarcinoma Based on Differential Expression of Select miRNA in Plasma and Bile. American Journal of Gastroenterology, 2014, 109, 1942-1952.	0.2	100
42	Thiol-ene hydrogels as desmoplasia-mimetic matrices for modeling pancreatic cancer cell growth, invasion, and drug resistance. Biomaterials, 2014, 35, 9668-9677.	5.7	65
43	Pancreatic Cancer Stroma: Friend or Foe?. Cancer Cell, 2014, 25, 711-712.	7.7	164
44	Improving the Diagnostic Accuracy of Endoscopic Ultrasound–Guided Fine-Needle Aspiration Using MicroRNAs. Gastroenterology, 2014, 147, 930-932.	0.6	6
45	Signaling Pathways in Pancreatic Cancer. Critical Reviews in Eukaryotic Gene Expression, 2011, 21, 115-129.	0.4	34
46	MicroRNA-10b Expression Correlates with Response to Neoadjuvant Therapy and Survival in Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2011, 17, 5812-5821.	3.2	147
47	A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFÎ ² in pancreatic cancer cells. Cancer Biology and Therapy, 2011, 12, 198-207.	1.5	48
48	Fluorescence-Based Codetection with Protein Markers Reveals Distinct Cellular Compartments for Altered MicroRNA Expression in Solid Tumors. Clinical Cancer Research, 2010, 16, 4246-4255.	3.2	102
49	Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment. Journal of Clinical Oncology, 2009, 27, 5660-5669.	0.8	211
50	Analysis of MicroRNAs in Pancreatic Fine-Needle Aspirates Can Classify Benign and Malignant Tissues. Clinical Chemistry, 2008, 54, 1716-1724.	1.5	194
51	Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. Journal of Clinical Investigation, 2008, 118, 89-99.	3.9	149
52	Up-regulation of Transforming Growth Factor (TGF)-β Receptors by TGF-β1 in COLO-357 Cells. Journal of Biological Chemistry, 1998, 273, 7495-7500.	1.6	68
53	Effects of Dietary Manganese Deficiency on Rat Pancreatic Amylase mRNA Levels. Journal of Nutrition, 1990, 120, 1228-1234.	1.3	16